RPI-500

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameRPI-500
Drug Alias Namerhamnolipid (Rhamnopharma)RPI-500
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLipid metabolism modulators
TargetsUpdating
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRhamnopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRhamnopharma Inc
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A